Analyzing Surrozen (SRZN) and The Competition

Surrozen (NASDAQ:SRZN) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Surrozen to similar companies based on the strength of its profitability, valuation, institutional ownership, risk, dividends, analyst recommendations and earnings.

Valuation and Earnings

This table compares Surrozen and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Surrozen	$11.51 million	-$242.03 million	-0.72
Surrozen Competitors	$732.46 million	$13.53 million	-10.01

Surrozen’s competitors have higher revenue and earnings than Surrozen. Surrozen is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

66.6% of Surrozen shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 31.7% of Surrozen shares are owned by company insiders. Comparatively, 12.9% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Surrozen and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1	1	4	1	2.71
Surrozen Competitors	9782	15046	45274	1571	2.54

Surrozen presently has a consensus target price of $48.33, suggesting a potential upside of 66.55%. As a group, “Biotechnology” companies have a potential upside of 99.71%. Given Surrozen’s competitors higher probable upside, analysts plainly believe Surrozen has less favorable growth aspects than its competitors.

Risk & Volatility

Surrozen has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Comparatively, Surrozen’s competitors have a beta of 1.11, indicating that their average share price is 11% more volatile than the S&P 500.

Profitability

This table compares Surrozen and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Surrozen	-2,885.33%	N/A	-93.62%
Surrozen Competitors	-9,054.47%	-198.89%	-30.64%

Summary

Surrozen beats its competitors on 7 of the 13 factors compared.

About Surrozen

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.